Primary biliary cholangitis (formerly primary biliary cirrhosis) is a chronic, progressive, autoimmune, cholestatic liver disease more common in middle-aged women. It is characterized by destruction of small to medium bile ducts leading to cholestasis and frequently, end-stage liver disease.
Diagnostic features are chronic biochemical cholestasis, presence of antimitochondrial antibodies and the characteristic liver biopsy findings.


Primary%20biliary%20cholangitis Diagnosis


  • At present, the diagnosis is most often made in an asymptomatic patient who presents with abnormal lab results (eg abnormal liver biochemistry profile and/or the presence of AMA) on a routine checkup or as part of workup for an associated illness

Physical Examination

  • In the early stages of disease, findings may be normal
  • Abnormal findings increase as the disease progresses

Portal Hypertension

  • Patients may present initially with variceal hemorrhage secondary to portal hypertension, which may be of a cirrhotic or non-cirrhotic nature
  • Anemia may develop from occult bleeding of varices

Stigmata of Liver Disease

  • The following may be present: Spider nevi, palmar erythema, muscle wasting, peripheral edema, parotid gland enlargement, gynecomastia, testicular atrophy, Dupuytren contracture

Signs of Malabsorption of Fat-Soluble Vitamins

  • Results from insufficient biliary secretion of bile acids
  • Neurological impairment and electromyograph changes secondary to vitamin E malabsorption
  • Rarely, night blindness and osteomalacia are present in PBC patients

Other Possible Findings in Patients with PBC

  • Xanthomata
    • Cholesterol deposits in the skin, they often occur around the eyes but may also be found on the palms, buttocks and heels
    • May be associated with hypercholesterolemia and hyperlipidemia that occur with PBC 
  • Hyperpigmentation, splenomegaly, hematemesis, melena, abdominal fullness
  • Urinary tract infections
    • Usually asymptomatic but recurrent
    • Etiologic agents are usually Gram-negative organisms, ie Enterobacteriaceae
    • Cross reactivity between antigens on the bacterial wall and cell mitochondria is postulated to be the cause

Signs of Metabolic Bone Disease

  • A patient with PBC may present with osteoporosis while remaining asymptomatic from the liver disease
    • An elevated alkaline phosphatase (ALP) level in a patient with osteoporosis should alert a physician of the possibility of PBC 
  • PBC patients may have associated pancreatic insufficiency and celiac disease which may aggravate vitamin D malabsorption, contributing to osteoporosis
  • Decreased osteoblastic activity and increased osteoclastic activity lead to development of osteoporosis in PBC patients

Laboratory Tests

  • At least 2 of the following criteria should be present for the diagnosis of PBC: Biochemical cholestasis with elevated ALP, presence of AMA, and the characteristic liver biopsy findings

Serum Chemistry

Alkaline Phosphatase (ALP)

  • High ALP of hepatic origin signifying intrahepatic cholestasis is the most common biochemical abnormality in PBC 
    • >1.5 times the upper limit of normal (ULN) for >24 weeks
  • Response to therapy may be seen with an ALP level <2x ULN with treatment 

Gamma-Glutamyl Transpeptidase (GGT)

  • Levels are determined to confirm hepatic origin of high ALP levels


  • Elevated bilirubin levels occur late in the course of disease
  • High bilirubin levels signify disease progression and are used as a predictor of prognosis


  • Total serum cholesterol levels may go up as a result of chronic cholestasis
  • The high-density lipoprotein (HDL) fraction is increased, which is the reason why PBC patients do not have a higher risk for atherosclerosis

Antimitochondrial Antibodies (AMA)

  • The presence of AMA in the serum, often in high titers (≥1:40), is the hallmark of PBC
  • AMA, which target different mitochondrial enzymes, are found in up to 95% of PBC patients
  • The simplest test for detection of AMA is immunofluorescence, but newer tests eg enzyme-linked immunosorbent assay (ELISA) and immunoblotting are more specific and sensitive
  • Sensitivity and specificity of AMA for PBC is >95%
  • Patients with an elevated ALP and normal hepatobiliary ultrasound should undergo serum testing for AMA


Hepatobiliary Ultrasound (US)

  • US of the liver and biliary tract should be done to differentiate intrahepatic versus extrahepatic cholestasis
  • Bile ducts appear normal in patients with PBC
  • A dilated biliary system characterizes biliary obstruction and is not consistent with PBC 
  • PBC patients may have nonspecific findings on US, eg increased echogenicity of liver parenchyma and portal lymphadenopathy
  • Portal hypertension may be present, as evidenced by a nodular liver appearance, ascites and intra-abdominal varices

Transient Elastography

  • Accurate in diagnosing advanced fibrosis in PBC patients 
  • May be used in assessing prognosis and response to therapy 
    • Also used to risk-stratify patients: Liver stiffness progression is a predictor of poor outcome

Liver Biopsy

  • Findings on liver biopsy for PBC are very specific, especially in non-cirrhotic patients: Nonsuppurative destructive cholangitis and interlobular destruction of the bile ducts  
  • A liver biopsy is essential in the following patients to confirm or rule out PBC:
    • Low-titer (<1:40) or negative AMA  
    • Transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] are prominently increased 
    • Patient with a history of taking potentially hepatotoxic drugs
  • In contrast, a patient positive for AMA with a titer ≥1:40 plus typical symptoms and biochemical derangements may not require a liver biopsy to make the diagnosis of PBC
    • However, the liver biopsy may provide additional information about the stage of the illness and the patient’s prognosis 
  • For biopsy findings to provide a precise evaluation of bile duct damage, it is very important that the specimen has an adequate number (at least 10-15) of portal tracts 
  • Not to be used to monitor patient’s response to therapy

Disorders Associated with PBC

  • Sicca syndrome
    • Symptoms include xerophthalmia, xerostomia, dental caries, dysphagia, dyspareunia and tracheobronchitis
    • Investigate symptoms by direct questioning
    • Sicca symptoms are present in about ¾ of PBC patients
  • Thyroid dysfunction
    • Thyroid disease is also of autoimmune origin
    • Symptoms usually precede diagnosis of PBC  
  • CREST (C-calcinosis cutis, R-Raynaud’s phenomena, E-esophageal dysmotility, S-sclerodactyly, T-telangiectasia) syndrome
    • Complete form is rarely seen in PBC patients
    • Raynaud’s syndrome by itself is seen more often and is more problematic for patients who live in cold climates
  • Rheumatoid factor is detected in 25% of PBC patients
    • Symptomatic arthritis is less common
  • Celiac disease and inflammatory bowel disease (IBD) occur rarely

Further Workup for AMA-Negative Patients with Clinical Suspicion of PBC

  • Certain patients may have clinical, biochemical and histologic evidence of PBC but consistently test negative for AMA 
    • Further workup should be considered in patients negative for AMA but with high ALP and normal biliary US
  • These patients most likely do have PBC but have an antibody profile more consistent with autoimmune hepatitis (AIH), a variant known as PBC/AIH overlap
    • In patients with PBC/AIH overlap, the predominant histological pattern of injury should be targeted for treatment 
  • Patients with the above characteristics should undergo further tests

Antinuclear Antibodies (ANA) and/or Smooth Muscle Antibodies (SMA)

  • AMA-negative patients clinically suspicious for PBC should be tested for ANA and SMA
    • Nearly half of PBC patients may be positive for ANA and SMA
  • High titers of ANA and/or SMA are more common in AIH, but may be present in AMA-negative patients with a high clinical suspicion of PBC 
    • In these patients, a thorough review of liver biochemistry and biopsy findings is imperative in making a correct diagnosis; patients with AIH have a serum ALT level of >5x ULN

Immunoglobulins (Ig)

  • Testing for the immunoglobulin pattern is probably only needed in unconvincing cases
  • A high level of IgM is usual in PBC
  • IgA levels are usually normal but PBC has been found in patients who are IgA deficient
  • In AMA-negative PBC, however, the IgG fraction is more likely to be elevated than the IgM fraction
    • AIH has serum IgG levels >2x ULN


  • Magnetic resonance cholangiopancreatography (MRCP) can be performed in patients with unexplained cholestasis  
  • Endoscopic US, an alternative to MRCP, can be used in evaluating distal biliary disease

Liver Biopsy

  • May be done in patients with unexplained intrahepatic cholestasis after serologic screening and additional imaging     
  • Considered in ruling out concomitant AIH in PBC patients with highly elevated ALT and/or IgG 
  • Not required in diagnosing AMA-negative PBC if other criteria, eg cholestatic liver tests and PBC-specific autoantibodies (sp100 or gp210), are met
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 19 hours ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.
16 Sep 2020
XOFLUZA – Baloxavir marboxil 20 mg and 40 mg FC tab